175 related articles for article (PubMed ID: 28011623)
1. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.
Wragg JW; Heath VL; Bicknell R
Cancer Res; 2017 Feb; 77(4):1008-1020. PubMed ID: 28011623
[TBL] [Abstract][Full Text] [Related]
2. Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS
Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
5. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E
J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816
[TBL] [Abstract][Full Text] [Related]
6. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
Wang D; Xiao F; Feng Z; Li M; Kong L; Huang L; Wei Y; Li H; Liu F; Zhang H; Zhang W
Breast Cancer Res; 2020 Sep; 22(1):103. PubMed ID: 32993785
[TBL] [Abstract][Full Text] [Related]
9. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
10. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
[TBL] [Abstract][Full Text] [Related]
12. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Guerin E; Man S; Xu P; Kerbel RS
Cancer Res; 2013 May; 73(9):2743-8. PubMed ID: 23610448
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Rovida A; Castiglioni V; Decio A; Scarlato V; Scanziani E; Giavazzi R; Cesca M
Mol Cancer Ther; 2013 Oct; 12(10):2237-47. PubMed ID: 23918831
[TBL] [Abstract][Full Text] [Related]
17. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Mena AC; Pulido EG; Guillén-Ponce C
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
[TBL] [Abstract][Full Text] [Related]
18. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS; George J; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin PA; House CM; Chakravarty P; Gorringe KL; Campbell IG; ; Okamoto A; Birrer MJ; Huntsman DG; de Fazio A; Kalloger SE; Balkwill F; Gilks CB; Bowtell DD
Clin Cancer Res; 2011 Apr; 17(8):2538-48. PubMed ID: 21343371
[TBL] [Abstract][Full Text] [Related]
19. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
[TBL] [Abstract][Full Text] [Related]
20. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
Yin T; He S; Shen G; Wang Y
Oncol Res; 2014; 22(3):139-45. PubMed ID: 26168132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
